Cargando…

Effects of three blood purification methods on serum fibroblast growth factor-23 clearance in patients with hyperphosphatemia undergoing maintenance hemodialysis

The aim of the present study was to investigate the effects of three blood purification methods on fibroblast growth factor-23 (FGF-23) clearance in patients with hyperphosphatemia undergoing maintenance hemodialysis (MHD). In addition, the correlation between serum FGF-23 and phosphorus (Pi) levels...

Descripción completa

Detalles Bibliográficos
Autores principales:	MIAO, LI-YING, ZHU, BIN, HE, XIAO-ZHOU, LIU, JIN-FENG, JIN, LI-NA, LI, XIU-RONG, XUE, LI-NA, HUANG, TIAN, SHEN, JIAN-QIN, XING, CHANG-YING
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2014
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964936/ https://www.ncbi.nlm.nih.gov/pubmed/24669256 http://dx.doi.org/10.3892/etm.2014.1543

Ejemplares similares

The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia
por: Block, Geoffrey A, et al.
Publicado: (2019)

Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis
por: Chen, Lan, et al.
Publicado: (2018)

A Case of Hyperphosphatemia and Elevated Fibroblast Growth Factor 23: A Brief Review of Hyperphosphatemia and Fibroblast Growth Factor 23 Pathway
por: Wang, Joseph, et al.
Publicado: (2017)

Efficacy of crushed lanthanum carbonate for hyperphosphatemia in hemodialysis patients undergoing tube feeding
por: Kitajima, Yukie, et al.
Publicado: (2011)

Control of hyperphosphatemia and maintenance of calcemia in CKD
por: Carvalho, Aluizio Barbosa, et al.
Publicado: (2021)

Fibroblast growth factor-23 levels in maintenance hemodialysis patients in India
por: Anandh, U., et al.
Publicado: (2017)

Low calcium dialysate combined with CaCO(3) in hyperphosphatemia in hemodialysis patients
por: GAO, ZHUO, et al.
Publicado: (2013)

Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysis
por: Vasantha, J., et al.
Publicado: (2011)

Magnesium Modifies the Cardiovascular Mortality Risk Associated with Hyperphosphatemia in Patients Undergoing Hemodialysis: A Cohort Study
por: Sakaguchi, Yusuke, et al.
Publicado: (2014)

Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial
por: Inaba, Masaaki, et al.
Publicado: (2021)

Association between serum fibroblast growth factor‐23 concentration and development of hyperphosphatemia in normophosphatemic dogs with chronic kidney disease
por: Miyakawa, Hirosumi, et al.
Publicado: (2021)

NaPi-IIb Inhibition for Hyperphosphatemia in CKD Hemodialysis Patients
por: Maruyama, Sonomi, et al.
Publicado: (2020)

Correlation of serum levels of fibroblast growth factor 23 and Klotho protein levels with bone mineral density in maintenance hemodialysis patients
por: Zheng, Shubei, et al.
Publicado: (2018)

Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis
por: Savica, Vincenzo, et al.
Publicado: (2008)

Meta-analysis of the efficacy and safety of sevelamer as hyperphosphatemia therapy for hemodialysis patients
por: Zeng, Qian, et al.
Publicado: (2023)

Sarcopenia and echocardiographic parameters for prediction of cardiovascular events and mortality in patients undergoing maintenance hemodialysis
por: Zhang, Mengyan, et al.
Publicado: (2022)

Letter Regarding “Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial”
por: Aoki, Yuki, et al.
Publicado: (2022)

Effect of low-dose lanthanum carbonate on calcium and phosphorus metabolism in Asian Patients with end-stage renal disease, maintenance hemodialysis and hyperphosphatemia
por: Cui, Xiaofei, et al.
Publicado: (2022)

Hyperphosphatemia is associated with patency loss of arteriovenous fistula after 1 year of hemodialysis
por: Moon, Ju-Young, et al.
Publicado: (2015)

Calcium Acetate or Calcium Carbonate for Hyperphosphatemia of Hemodialysis Patients: A Meta-Analysis
por: Wang, Yong, et al.
Publicado: (2015)

Hyperphosphatemia is not significantly associated with increased all-cause mortality in Korean hemodialysis patients
por: Wakasugi, Minako, et al.
Publicado: (2018)

In Reply to “Letter Regarding ‘Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial’”
por: Inaba, Masaaki, et al.
Publicado: (2022)

Hyperphosphatemia and Cardiovascular Disease
por: Zhou, Chao, et al.
Publicado: (2021)

Vancomycin dosing in patients undergoing maintenance hemodialysis
por: Rymarz, Aleksandra, et al.
Publicado: (2014)

Serum Fibroblast Growth Factor 21 Level Is Associated with Aortic Stiffness in Patients on Maintenance Hemodialysis
por: Chiu, Liang-Te, et al.
Publicado: (2022)

Safety of Low-calcium Dialysate and its Effects on Coronary Artery Calcification in Patients Undergoing Maintenance Hemodialysis
por: Wen, Yang, et al.
Publicado: (2018)

Hyperphosphatemia and its relationship with blood pressure, vasoconstriction, and endothelial cell dysfunction in hypertensive hemodialysis patients
por: Jung, Jinwoo, et al.
Publicado: (2022)

Cognitive Dysfunction and Its Risk Factors in Patients Undergoing Maintenance Hemodialysis
por: Tian, Xiaolin, et al.
Publicado: (2022)

The significance of serum levels of soluble interleukin-2 receptor in patients undergoing maintenance hemodialysis
por: Chen, Xiaohong, et al.
Publicado: (2020)

Correlation study of FGF23/D-serine in maintenance hemodialysis patients with combined hearing impairment
por: Yuan, Dunlu, et al.
Publicado: (2023)

Tenapanor Improves Long-Term Control of Hyperphosphatemia in Patients Receiving Maintenance Dialysis: the NORMALIZE Study
por: Silva, Arnold L., et al.
Publicado: (2023)

Significance of Adipose Tissue Maintenance in Patients Undergoing Hemodialysis
por: Okuno, Senji
Publicado: (2021)

The importance of muscle mass in predicting intradialytic hypotension in patients undergoing maintenance hemodialysis
por: Son, Hyung Eun, et al.
Publicado: (2022)

Correlation of Serum FGF23 and Chronic Kidney Disease-Mineral and Bone Abnormality Markers With Cardiac Structure Changes in Maintenance Hemodialysis Patients
por: Zeng, Dewang, et al.
Publicado: (2023)

Relationship between the triglyceride–glucose index and coronary artery calcification in asymptomatic, non-diabetic patients undergoing maintenance hemodialysis
por: Ding, Hong, et al.
Publicado: (2023)

Both hypophosphatemia and hyperphosphatemia are associated with increased mortality in septic patients
por: Liu, Zheng, et al.
Publicado: (2022)

Serum Hepcidin-25 and All-Cause Mortality in Patients Undergoing Maintenance Hemodialysis
por: Zou, Lu-Xi, et al.
Publicado: (2021)

Evaluation of methods to eliminate analytical interference in multiple myeloma patients with spurious hyperphosphatemia
por: Tian, Xin, et al.
Publicado: (2023)

Changes in Serum Concentrations of Fibroblast Growth Factor 23 and Soluble Klotho in Hemodialysis Patients after Total Parathyroidectomy
por: Liao, Shang-Chih, et al.
Publicado: (2016)

Water-Soluble Vitamins Status in Patients Undergoing Maintenance Hemodialysis
por: Kaczkan, Małgorzata, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_teipd42vl7eee2sphvti1i8iiq